Adiposity and Endothelin Receptor Function (END-RF)

Augusta University

Status and phase

Active, not recruiting

Early Phase 1

Conditions

Hypertension

Treatments

Drug: Candesartan

Drug: Placebo

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT03583866

1148277

5P01HL069999 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.

Full description

The proposed study is designed to investigate the influence of adiposity on ETB receptor function and subsequent vascular responses. The combination of ET-1, ET-3, and the respective ETA and ETB receptor antagonists will be used to provide insight into the mechanisms of ETB receptor dysfunction in the presence of adiposity. Previous studies have revealed elevations in circulating ET-1 in obese individuals; therefore, we predict that obese subjects will exhibit 1) ETB receptor dysfuncton compared to lean subjects and 2) an improvement in ETB receptor dysfunction following treatment with Candesartan.

Enrollment

25 patients

Sex

All

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

• If you are an adult between the ages of 18-40 year old

Exclusion criteria

Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease
Evidence of pregnancy
Using medications that affect vascular tone (i.e., nitrates, etc.)
Use of any anticoagulants (i.e. aspirin)
Anemia
If you are postmenopausal
If you have uncontrolled hypertension (treated resting SBP >140 mm Hg or DBP >90 mm Hg)